Search Results
Oct 23, 2025, 15:23 ET DCAI udvider AI-infrastrukturtilbuddet med WEKA's integrerede lagringstjenester
kompromis med suverænitet, sikkerhed eller ydeevne. Forening af beregning og lagring Indtil nu var kunderne primært afhængige af DCAI for at få adgang til avanceret computerkraft til at træne og implementere deres AI-modeller i stor skala. Med indførelsen
More news about: WEKA
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
Schram AM, Goto K, Kim DW, et al. Efficacy of zenocutuzumab in NRG1 fusion–positive cancer. N Engl J Med. 2025;392:566-76.
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 12:37 ET VIRTUSA UDNÆVNER HARPREET ARORA TIL CHEF FOR STORBRITANNIEN, EUROPA OG MELLEMØSTEN
rolle i ledelsen af forretningsteamet i forbindelse med overtagelsen af Capco og var ansvarlig for at skabe forretningsværdi på tværs af Wipros overtagne enheder. Før Wipro arbejdede Arora i ti år hos Infosys, hvor han var med til at øge overskuddet inden for finansielle tjenesteydelser
More news about: Virtusa Corporation
Oct 23, 2025, 12:32 ET VIRTUSA UTSER HARPREET ARORA TILL CHEF FÖR STORBRITANNIEN, EUROPA OCH MELLANÖSTERN
plattformstekniskt tjänsteföretag som gör upplevelser bättre med hjälp av teknik. Vi hjälper organisationer att växa snabbare, mer lönsamt och mer hållbart genom att omforma företag genom domändrivna lösningar. Vi kombinerar strategi, design och teknik, med stöd av oöverträffad expertis vid skärningspunkten mellan
More news about: Virtusa Corporation
Oct 23, 2025, 12:28 ET VIRTUSA UTNEVNER HARPREET ARORA SOM LEDER FOR STORBRITANNIA, EUROPA OG MIDTØSTEN
og strategisk verdi i globale bedrifter. «Vi er kjempefornøyde med å ønske Harpreet velkommen til Virtusas lederteam. Hans dype kompetanse innen teknologiledet konsulentvirksomhet, kombinert med hans lange erfaring innen å orkestrere komplekse oppkjøp og drive vekst i konkurransedyktige
More news about: Virtusa Corporation
Oct 23, 2025, 09:45 ET Southeastern Oklahoma State University Expands Special Education Offerings with New Graduate Concentration in Autism and Developmental Disabilities
https://online.se.edu/programs/education/med-sped-counseling/autism-developmental-disabilities. Applications are open, and the Spring 2026 cohort is now accepting applicants.
More news about: Risepoint
Oct 22, 2025, 18:29 ET Tricoci Expands Its Beauty Portfolio with the Introduction of Tricoci Med Spa
"Tricoci Med Spa is a natural extension of that trust — where beauty meets expertise, and clinical precision is delivered with the same personalized care and refinement that define our brand." In an industry often driven by fleeting trends, Tricoci Med Spa
More news about: Tricoci Salon and Spa
Oct 22, 2025, 08:55 ET Rejuvn8 Aesthetics Expands to Rochester, NY -- Grand Opening January 2026
Robotham, NP-C, Rejuvn8 Aesthetics has earned a reputation for excellence in advanced, non-surgical aesthetic medicine. Rejuvn8 clinics have been voted Best Med Spa from 2023-2025 which is a testament to their patient focused care. The Rochester expansion marks another milestone in the brand's continued growth,
More news about: Rejuvn8 Aesthetics
Oct 21, 2025, 15:59 ET Elanco Saúde Animal lança Varenzin(TM), primeiro medicamento veterinário oral para tratar anemia em gatos com doença renal crônica (DRC)
Chalhoub S. Langston C. Eatroff A. Anemia of Renal Disease: what it is, what to do and what's new. J. Feline Med Surg. 2011 Sep: 13 (9): 629-40 2
More news about: Elanco Saúde Animal
Oct 21, 2025, 02:00 ET Haut.AI Launches Ground Breaking GenAI Powered Skin Aging Simulation
Noom Health partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Weight with SmartRx, Noom Weight, Noom weight with GLP-1Rx, Noom Diabetes, and Noom Diabetes Prevention Program, to millions. Noom has received
More news about: Haut.AI
Oct 20, 2025, 12:38 ET IgNobel 'Butt Breathing' Idea from 2024 Moves Closer to Real Treatment
In fact, positive results were published Oct. 20, 2025, in the journal Med regarding the first human clinical trial to evaluate the potential benefits of "enteral ventilation." "This is the first human
More news about: Cincinnati Children's Hospital Medical Center
Oct 20, 2025, 12:30 ET Highmark and Noom collaborate to improve member health through behavior change and personalized support
Noom Health partners with top health plans and employers to offer a suite of solutions, including Noom Med, Noom Med with SmartRx, Noom Weight, Noom Weight with GLP-1Rx, Noom Diabetes, and Noom Diabetes Prevention Program, to millions. Noom has received multiple
More news about: Highmark Health
Oct 20, 2025, 09:20 ET Accuray Accelerates Transformation Efforts with Appointment of Experienced Executive Leaders to Drive Performance and Growth
company for long-term success," said Joe Whitters, Chairman of the Board. "Steve's proven record of operational excellence and value creation at leading med-tech companies makes him exceptionally well suited to guide Accuray through its next phase of growth. The Board is committed to disciplined execution
More news about: Accuray Incorporated
Oct 20, 2025, 08:00 ET RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor
JM, Chiarello E, Ponce de Leon D. Treatment patterns and sequencing in patients with rheumatic diseases: a retrospective claims data analysis. Curr Med Res Opin. 2021;37(12):2185-2196. doi:10.1080/03007995.2021.1981278 Migliore A, Pompilio G, Integlia D, Zhuo J, Alemao
More news about: AbbVie
Oct 20, 2025, 06:10 ET BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 600 in-house engineers,
More news about: BTL
Oct 20, 2025, 06:00 ET Realtor.com®: Down Payments Steady as Average FICO Scores Remain At 10-Year High
Med. Down Payment ($ amt)
More news about: Realtor.com
Oct 20, 2025, 04:59 ET BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
Founded in 1993, BTL is a global leader in medical devices, providing innovative solutions in dermatology, plastic surgery, med spas, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, OB/GYN, and more. With 200+ patents and over 600 in-house engineers,
More news about: BTL
Oct 20, 2025, 03:00 ET AP Pension vælger Cognizant til BPO- og RPA-tjenester som led i en flerårig transformation
har i dag offentliggjort et nyt partnerskab med AP Pension, et af Danmarks førende livs- og pensionsselskaber. Samarbejdet omfatter Business Process Outsourcing (BPO), Robotic Process Automation (RPA) og optimering af udvalgte administrative processer med det formål at styrke AP Pensions kapacitet til
More news about: Cognizant Technology Solutions Corporation
Oct 19, 2025, 03:24 ET 從身心健康到學業表現--為何香港家長要約束子女使用社交媒體及電子產品？
Health 2019;16:937. [9] Manferdelli G, La Torre A, Codella R. Outdoor physical activity bears multiple benefits to health and society. J Sports Med Phys Fitness 2019;59:868-879.
More news about: Look Up Hong Kong
Oct 17, 2025, 17:39 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes.N Engl J Med. 2025;392(20):2001-2012. Rybelsus® (oral semaglutide): US Prescribing Information. Available at:
More news about: Novo Nordisk
Oct 17, 2025, 17:15 ET FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
Inc. McGuire DK, Marx N, Mulvagh SL, et al. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes.N Engl J Med. 2025;392(20):2001-2012. Rybelsus® (oral semaglutide): US Prescribing Information. Available at:
More news about: Novo Nordisk
Oct 17, 2025, 16:00 ET FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
clinical burden of chronic rhinosinusitis with nasal polyposis. Curr Med Res Opin. 2020;36(11):1897-1911. Lipworth, BJ, Han JK, et al. Tezepelumab in adults with severe, uncontrolled CRSwNP. N Engl J Med. 2025. Lipworth, BJ, Han JK, et al. Efficacy
More news about: Amgen
Oct 16, 2025, 23:13 ET Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization
innovation extends beyond pharmaceuticals. Wang Qunbin shared that in the field of cultural tourism and consumption, Fosun Tourism Group's (FTG) Club Med have continued to advance AI-driven digital transformation. The G.M Copilot conversational AI assistant, which provides 24/7 instant and personalized
More news about: Fosun
Oct 16, 2025, 19:38 ET Ericsson och Export Development Canada stärker Kanadas ledarskap inom nästa generations nätverk med ett partnerskapsavtal på 3 miljarder USD
ett av Ericssons viktigaste nav för global forskning och utveckling, och detta partnerskap med Export Development Canada ger oss möjlighet att ta vårt ledarskap till nästa nivå. Genom att stärka vårt samarbete med kanadensiska företag, universitet och myndighetspartners kan vi snabba på genombrott inom
More news about: Ericsson
Oct 16, 2025, 17:24 ET The Inner Circle acknowledges, Courtney Rollings Latham, M.Ed, BCBA as a Pinnacle Professional Member Inner Circle of Excellence
multimedia:https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-courtney-rollings-latham-med-bcba-as-a-pinnacle-professional-member-inner-circle-of-excellence-302586773.html
More news about: The Inner Circle